UniQure N.V. (QURE) shares tumbled 44% in premarket trading Monday after the FDA said the company’s Huntington’s disease gene therapy data was insufficient for a marketing application.
The regulatory setback threatens to delay approval of AMT-130, UniQure’s most advanced therapy that represents a critical revenue opportunity for the Netherlands-based biotech company.
Key Takeaways
- FDA requires randomized, controlled study versus single-arm trial data
- UniQure stock down 44% premarket, extending recent volatility
- Company plans Type B meeting with regulators in Q2
Market Reaction & Context
UniQure’s sharp decline follows mounting pressure on gene therapy stocks amid increased FDA scrutiny. The company’s shares have fallen approximately 58% year-to-date, underperforming the broader biotech sector 1.
Following a January meeting with regulators, UniQure said the FDA “strongly recommended” conducting a prospective, randomized, double-blind, sham surgery-controlled study rather than relying on single-arm trial data compared to external controls 2.
Regulatory Hurdles Mount
The FDA’s position represents a significant shift from previous communications. UniQure had been working extensively with the agency to ensure proper data collection for an approval application.
AMT-130 is administered through a burr hole drilled into patients’ skulls, delivering the therapy directly to brain tissue. This invasive delivery method may be contributing to the FDA’s heightened safety and efficacy requirements.
Industry-Wide Pressure
The setback comes as FDA Commissioner Martin Makary has defended the agency’s stricter approach to rare disease therapies. During a recent CNBC appearance, Makary referenced pressures to approve treatments involving skull procedures, though he did not specifically name UniQure 3.
“We’re not going to go ahead and approve something like that that has morbidity associated with it,” Makary said, referring to therapies requiring invasive delivery methods.
Company Response
UniQure said it intends to continue working with the FDA on Phase III program design. The company plans to request a Type B meeting in the second quarter of 2026 to discuss potential study designs.
Wall Street analysts noted the FDA’s “steadfast defense” of its position suggests limited flexibility on reconsidering recent regulatory decisions without specific political pressure 4.
Financial Impact
The regulatory delay creates significant uncertainty around UniQure’s revenue timeline. AMT-130 represents the company’s lead asset, with Huntington’s disease affecting approximately 30,000 people in the United States.
UniQure reported fourth-quarter 2025 revenue of $16.1 million, slightly above analyst estimates of $15.8 million, though the company posted a net loss of $3.46 per share 5.
Not investment advice. For informational purposes only.
References
1Adam Feuerstein (March 2, 2026). “UniQure plans to seek approval for Huntington’s therapy still blocked by FDA”. STAT News. Retrieved March 2, 2026.
2WKZO (March 2, 2026). “FDA tells uniQure early trial data insufficient for brain disorder therapy application”. WKZO. Retrieved March 2, 2026.
3Jacob Bell (February 27, 2026). “UniQure falls further on Makary comments”. BioPharma Dive. Retrieved March 2, 2026.
4Adriano Marchese (March 2, 2026). “UniQure Down in Premarket as FDA Says Huntington’s Gene-Therapy Data Falls Short”. MarketScreener. Retrieved March 2, 2026.
5Louis Juricic (February 26, 2026). “UniQure stock tumbles on FDA comments about gene therapy trial”. Investing.com. Retrieved March 2, 2026.